Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclarion, Inc. (ACON)
NASDAQ:ACON
Holding ACON?
Track your performance easily
ACON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.16 - $9.90
Previous Close$0.19
Volume179.60K
Average Volume (3M)590.65K
Market Cap
$1.67M
Enterprise Value$1.28M
Total Cash (Recent Filing)$1.17M
Total Debt (Recent Filing)$777.09K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 25, 2023EPS Estimate
-$1.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding9,610,000
10 Day Avg. Volume818,389
30 Day Avg. Volume590,652
Standard Deviation0.26
R-Squared0.00696
Alpha-0.12
Financial Highlights & Ratios
Price to Book (P/B)1.09
Price to Sales (P/S)31.35
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.30
Enterprise Value/Gross Profit-3.94K
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$1.60Price Target Upside764.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aclarion, Inc. News
Bulls Say, Bears Say
Bulls Say
Commercial AgreementAclarion announced it established a commercial agreement for Nociscan with Sheridan Community Hospital in Sheridan, Michigan.
Market OpportunityLower back pain represents the single largest spend in healthcare. Over 550,000 lower back surgeries are performed each year in the US, and the US lumbar spine diagnostics and treatment market is estimated at $40 billion annually.
Private Payor CoverageACON now has coverage for its Nociscan by three of the four largest private payors in the UK, providing access to ~60% of patients with private health insurance.
Bears Say
Capital RaiseAclarion will need to raise significant capital to fund its roadmap.
Cash BurnWith only $2.1 million in cash and a burn rate of $1.5 million per quarter, Aclarion faces significant financial challenges.
Price TargetThe price target is being lowered to $1.00 from $1.50 due to anticipated dilution from an expected capital raise.
---
Ownership Overview
3.33%
Insiders
0.04% Mutual Funds
0.14% Other Institutional Investors
96.48% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ACON FAQ
What was Aclarion, Inc.’s price range in the past 12 months?
Aclarion, Inc. lowest stock price was $0.16 and its highest was $9.90 in the past 12 months.
What is Aclarion, Inc.’s market cap?
Currently, no data Available
When is Aclarion, Inc.’s upcoming earnings report date?
Aclarion, Inc.’s upcoming earnings report date is Aug 25, 2023 which is 392 days ago.
How were Aclarion, Inc.’s earnings last quarter?
Currently, no data Available
Is Aclarion, Inc. overvalued?
According to Wall Street analysts Aclarion, Inc.’s price is currently Undervalued.
Does Aclarion, Inc. pay dividends?
Aclarion, Inc. does not currently pay dividends.
What is Aclarion, Inc.’s EPS estimate?
Aclarion, Inc.’s EPS estimate is -$1.44.
How many shares outstanding does Aclarion, Inc. have?
Aclarion, Inc. has 9,035,671 shares outstanding.
What happened to Aclarion, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aclarion, Inc.?
Currently, no hedge funds are holding shares in ACON
---
Aclarion, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-97.34%
12-Months-Change
Fundamentals
Return on Equity
-714.18%
Trailing 12-Months
Asset Growth
54.10%
Trailing 12-Months
Company Description
Aclarion, Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.
---
ACON Stock 12 Month Forecast
Average Price Target
$1.60
▲(764.86% Upside)
Technical Analysis
Brainstorm Cell Therapeutics
―
Cellectar Biosciences
―
Corbus Pharmaceuticals
―
Geron
―
Best Analysts Covering ACON
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-50.81%
reiterated a buy rating 30 days ago
Copying Anthony Vendetti's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -50.81% per trade.
---